The J.POD biologics development and manufacturing facility located on Evotec’s Campus Curie in Toulouse, France, is the first in Europe.

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Several ASX companies are conducting clinical trials, and this has become a valuable sector and an asset to the Australian ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

Almaden—which was formerly part of IBM Research before launching as a standalone company in 2022 under Catalyze Dallas ...

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...